Characterization of rat liver microsomal metabolites of AM-630, a potent cannabinoid receptor antagonist, by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 39, Issue 6, 2004, Pages 672-681

  Zhang, Qiang ^a   Ma, Peng ^a   Wang, Weiqun ^b   Cole, Richard B ^b   Wang, Guangdi ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b UNIVERSITY OF NEW ORLEANS   (United States)

Author keywords

AM 630; CB2 antagonist; High performance liquid chromatography; Metabolism; Tandem mass spectrometry

Indexed keywords

BIOLOGICAL ORGANS; CHARACTERIZATION; DEHYDRATION; HYDROXYLATION; IONIZATION; LIQUID CHROMATOGRAPHY; METABOLISM; METABOLITES;

DEMETHYLATION; INCUBATION;

MASS SPECTROMETRY;

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALKYL GROUP; CANNABINOID RECEPTOR ANTAGONIST; DRUG METABOLITE; FUNCTIONAL GROUP; HYDROXYL GROUP; INDOLE; MORPHOLINE DERIVATIVE; PHENYL GROUP;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG DETERMINATION; DRUG METABOLISM; DRUG POTENCY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; RING OPENING; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INDOLES; LIVER; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS; RECEPTORS, CANNABINOID; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 3042736422     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.640     Document Type: Article

References (26)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002; 54: 161.
2. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 1986; 38: 75.
3. Keimowitz AR, Martin BR, Razdan RK, Crocker PJ, Mascarella SW, Thomas BF. QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency. J. Med. Chem. 2002; 43: 59.
4. Ward SJ, Baizman ER, Bell MR, Childers S, D'Ambra TE, Eissenstat MA, Estep KG, Haycock DA, Howlett A, Luttinger D, Miller M, Pacheco M. Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? NIDA Res. Monogr. 1990; 105: 425.
5. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Hermann JL. Antinociceptive (aminoalkyl)indoles. J. Med. Chem. 1995; 34: 1099.
6. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum; selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 1992; 264: 1352.
7. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumarm V, Estep KG, Olefirowicz EM, Wetzel JR, Alexander MD, Weaver JD III, Haycock DA, Luttinger DA, Casiano FM, Chippari SM, Koster JEJ, Stevenson I, Ward SJ. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 1995; 38: 3094.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1995; 258: 1946.
9. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995; 50: 83.
10. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere J-C, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994; 350: 240.
11. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere J-C, Le Fur G. SR 144528, the first potent and selective antagoinist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 1998; 284: 644.
12. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 1999; 6: 635.
13. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 1992; 35: 124.
14. Pacheco M, Childers SR, Arnold R, Casiano F, Ward SJ. Aminoalkylindoles: actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 1990; 257: 170.
15. Song ZJ, Slowey CA. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J. Pharmacol. Exp. Ther. 1998; 292: 136.
16. Bouaboula M, Dussossoy D, Casellas P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J. Biol. Chem. 1999; 274: 20 397-.
17. Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosing-5′-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther. 1998; 285: 553.
18. Tao Q, Abood ME. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the canabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J. Pharmacol. Exp. Ther. 1998; 285: 651.
19. Pertwee RG, Griffin G, Fernnando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 1995; 56: 1949.
20. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 1999; 126: 665.
21. Zhang Q, Ma P, Iszard M, Cole RB, Wang W, Wang G. In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab. Dispos. 2002; 30: 1077.
22. Zhang Q, Ma P, Wang G. in preparation for J. Pharmacol. Exp. Ther.
23. Dass C, Thimmaiah KN, Jayashree BS, Houghton PJ. Liquid secondary ionization mass spectrometry and collision-induced dissociation study of 2-chloro-N10-substituted phenoxazines. J. Mass Spectrom. 1997; 32: 1279.
24. Baillie TA, Neill E, Hughes H, Davies DL, Davies DS. In Stable Isotopes: Proceedings of the Third International Conference. Academic Press: New York, 1979; 415.
25. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to helthy human subjects. Drug Metab. Dispos. 2001; 29: 1136.
26. Madyastha KM, Gaikwad NW. Metabolic disposition of a monoterpene ketone, piperitenone, in rats: evidence for the formation of a known toxin, p-cresol. Drug Metab. Dispos. 1999; 27: 74.